Isleworth Healthcare Acquisition

Isleworth Healthcare Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on December 15, 2020 and is headquartered in St. Petersburg, FL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ST. PETERSBURG, Fla. , Aug. 25, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corp. (the "Company") (Nasdaq: ISLE; ISLEW) today announced that it has cancelled its special meeting of shareholders that was previously scheduled for August 26, 2022, and that it will redeem all of its outstanding ordinary shares that were included in the units issued in its initial public offering (the "public shares"), effective as of the close of business on August 29, 2022, as the Company will not consummate an initial business combination on or prior to September 1, 2022.

Isleworth Healthcare Acquisition Corp. Announces Cancellation of Special Meeting of Shareholders, Redemption of Public Shares and Subsequent Dissolution

ST. PETERSBURG, Fla. , June 30, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corporation (Nasdaq: ISLE)("Isleworth"), a special purpose acquisition company, today announced that it has entered into an agreement with Cytovia Holdings, Inc. ("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies (the "Termination Agreement") to terminate its previously announced Merger Agreement with Cytovia, which was executed in April 2022.

ISLEWORTH AND CYTOVIA TERMINATE MERGER AGREEMENT

Data supports further development of CYT-338 in relapsed/refractory multiple myeloma AVENTURA, Fla. and NATICK, Mass.

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 Congress

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK™ Cell Engager at EHA 2022 Congress

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

News for Isleworth Healthcare Acquisition Stock (ISLE)